STAAR Surgical Company

STAA Healthcare Medical Instruments & Supplies

In the quarter to June 2026, revenue grew 111.0%, EPS grew 147.1% and free cash flow grew 166.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

21.27 0.99 −4.45%
Market cap
$1.1B
P/E
304×
Fwd P/E
103×
Dividend yield
—
F-score
2/9
Altman Z
6.44
Beneish M
−3.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 1 4 5
ROE
(24.65%) (21.70%) (5.99%) 1.09%
ROA
(19.39%) (16.74%) (4.63%) 0.84%
ROIC
(37.54%) (30.31%) (7.49%) 4.67%
Return on Tangible Assets
(29.01%) (25.43%) (6.51%) 1.13%
Average Days of Receivables
95.14 76.32 102.03 105.84
Free Cash Flow per Share
(0.80) (0.81) (1.10) (0.13)
Free Cash Flow
(39.54) (40.05) (54.99) (6.75)
Capital Expenditures
(9.87) (5.82) (4.79) (3.50)
Other line items
Cash ROIC
(7.24%) (7.10%) (10.04%) (1.23%)
Accounts Receivable Turnover
2.80 3.74 4.79 5.11
Accounts Payable Turnover
5.05 4.03 6.66 6.15
Inventory Turnover
1.29 1.15 1.37 1.59
Average Days of Payables
55.60 74.09 47.30 61.96
Days of Inventory on Hand
322.83 355.23 270.80 215.34
Tax Rate
0.05 (0.02) 0.08 (0.78)
Research and Development Expense of Revenue
16.75% 16.73% 13.31% 11.28%
Selling, General and Administrative Expense of Revenue
84.40% 78.65% 61.45% 53.26%
Share Based Compensation of Revenue
11.55% 12.77% 10.12% 8.29%
Operating CF/Net income
0.31 0.43 2.39 (0.85)
Depreciation/Fixed assets
0.11 0.12 0.12 0.14
Capex/Depreciation
(1.24) (0.68) (0.58) (0.37)
Revenue per Share
4.65 4.83 5.82 6.75
Operating CF per Share
(0.60) (0.69) (1.01) (0.06)
Capex per Share
(0.20) (0.12) (0.10) (0.07)
Capex to Sales
0.04 0.02 0.02 0.01

Fold the line items

Columns are period end dates